心力衰竭中的铁:从分子见解到治疗含义
Konstantinos I Karampinos1, Dimitrios Farmakis1, Rijan Gurung2,3
1Department of Cardiology, Athens University Hospital Attikon, School of Medicine, National and Kapodistrian University of Athens, Greece.
Cardiovascular research
|January 30, 2026
概括
铁,一种由铁和脂质损伤驱动的细胞死亡形式,越来越多地与心力衰竭的进展有关. 向铁灭症显示出通过恢复心脏功能来治疗心力衰竭的前景.
科学领域:
- 心血管研究研究心血管研究
- 细胞死亡机制 细胞死亡机制
- 生物医学科学 生物医学科学
背景情况:
- 铁亡是一种受调节的细胞死亡途径,涉及铁诱导的脂质过氧化,在各种心力衰竭模型中普遍存在.
- 铁代谢失调,抗氧化剂缺乏和线粒体压力导致铁,导致心脏功能障碍和不良重塑.
- 虽然直接因果关系是有争议的,但铁灭症越来越多地被认为是导致心力衰竭进展的因素.
研究的目的:
- 批判性地分析现有的关于心力衰竭中的铁亡的文献.
- 提出一个新的机制框架",ferroptosis nexus",解释其在心脏功能障碍中的作用.
- 讨论转化障碍和未来的研究方向,用于心力衰竭中的铁亡调节.
主要方法:
- 文献综述和关键综合目前关于铁亡和心力衰竭的证据.
- 来自动物模型和人类研究的数据分析,包括转录和脂质组签名.
- 针对铁亡的治疗干预措施的评估,包括药理学剂和天然化合物.
主要成果:
- 铁亡是动物模型中各种心力衰竭病因的共同特征.
- 治疗干预措施,包括铁灭抑制剂和有效的心力衰竭药物,证明了救援效应.
- 人类心脏衰竭和心上脂肪组织显示出铁亡特异性的分子特征,在服用SGLT2抑制剂的患者中观察到活性降低.
结论:
- 铁亡是一个重要的途径,涉及到心力衰竭的发病,形成一个自我强化的"铁亡连接".
- 存在转化性挑战,但新出现的证据支持铁灭调制作为治疗策略.
- 使用标准化签名,先进的转录学和机制驱动的试验进行进一步的研究对于精确的心脏保护至关重要.
相关概念视频
01:29Heart Failure II: Pathophysiology
920
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
920
01:17Pathophysiology of Heart Failure
3.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.6K
01:27Heart Failure I: Introduction
882
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
882
01:22Heart Failure VI: Adjunct Therapies
336
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
336
01:22Heart Failure Drugs: Diuretics
966
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
966
01:30Heart Failure V: Medical Management
312
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
312